Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort (vol 15, pg 640, 2014)

Gianni L.; Eiermann W.; Semiglazov V

首页> 外文期刊>The lancet oncology >Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort (vol 15, pg 640, 2014)

【24h】

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort (vol 15, pg 640, 2014)

机译：Neoadjuvant and Adduvant Trastuzumab在Her2阳性局部晚期乳腺癌患者（诺亚）：随机控制优势试验的随访，并行HER2阴性队列（Vol 15，PG 640,2014）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The lancet oncology》 |2018年第12期|共1页
作者
Gianni L.; Eiermann W.; Semiglazov V;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort (vol 15, pg 640, 2014) [J] . Gianni L., Eiermann W., Semiglazov V The lancet oncology . 2018,第12期

机译：Neoadjuvant and Adduvant Trastuzumab在Her2阳性局部晚期乳腺癌患者（诺亚）：随机控制优势试验的随访，并行HER2阴性队列（Vol 15，PG 640,2014）
2. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. [J] . Gianni L, Eiermann W, Semiglazov V, The Lancet . 2010,第9712期

机译：对于HER2阳性的局部晚期乳腺癌患者，使用曲妥珠单抗的新辅助化疗联合曲妥珠单抗辅助与单独的新辅助化疗相比（NOAH试验）：一项平行HER2阴性队列的随机对照优势试验。
3. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): Follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort [J] . GianniL., EiermannW., SemiglazovV., The lancet oncology . 2014,第6期

机译：HER2阳性局部晚期乳腺癌（NOAH）患者的新辅助和辅助曲妥珠单抗：一项平行HER2阴性队列的随机对照优势试验的随访
4. Characterizing tumor changes during neoadjuvant treatment of locally advanced breast cancer patients (LABC) using dynamicenhanced magnetic resonance imaging (DE-MRI) [C] . Oana I. Craciunescu, Ellen L. Jones, Kimberly L. Blackwell, Society of Photo-Optical Instrumentation Engineers (SPIE);SPIE Proceedings . 2005

机译：使用动态增强磁共振成像（DE-MRI）表征局部晚期乳腺癌患者（LABC）新辅助治疗期间的肿瘤变化
5. Supportive Care for Patients with Breast Cancer by Using an Interactive App During Neoadjuvant Chemotherapy: A Randomized Controlled Trial [D] . Fjell, Maria. 2021

机译：通过在Neoadjuvant化疗期间使用互动性应用的乳腺癌患者的支持性护理：随机对照试验
6. Fluorouracil epirubicin and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised controlled phase 3 trial [O] . Aman U Buzdar, Vera J Suman, Funda Meric-Bernstam, -1

机译：氟尿嘧啶表柔比星和环磷酰胺（FEC-75）+紫杉醇+曲妥珠单抗vs紫杉醇+曲妥珠单抗+ FEC-75 +曲妥珠单抗作为HER2阳性乳腺癌（Z1041）患者的新辅助治疗：一项随机对照3期试验
7. Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5 [O] . John W. Smith, Marc E. Buyse, Priya Rastogi, 2017

机译：环磷酰胺蛋白与环磷酰胺，其次是多西紫杉醇与Trastuzumab和Bevacizumab为Neoadjuvant治疗，用于Her2阳性局部晚期乳腺癌，或作为HER2阳性病理阶段III乳腺癌的辅助治疗：NSABP基金会研究组的II期试验，FB-5

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort (vol 15, pg 640, 2014)

著录项

相似文献

相关主题

期刊订阅